Aidance Scientific, Inc. — FDA Warning Letter, 2026-10-01: Unapproved New Drugs
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
The FDA Center for Drug Evaluation and Research issued a warning letter to Aidance Scientific, Inc. (October 1, 2026, Reference 735346) regarding "Terragen HG Formula," marketed on the company's website and Amazon storefront as a treatment for genital herpes and associated symptoms. The FDA determined the product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act because it is not generally recognized as safe and effective for its labeled uses, and its marketing claims—including "genital sores treatment," "relief of swelling and pain," and "outbreak support"—establish drug intent regardless of homeopathic labeling. The agency noted that unapproved OTC drugs for sexually transmitted infections present serious public health risks, as patients may forgo appropriate medical care and unknowingly transmit infections to others.
Argus analysis
# FDA Warning Letter Analysis: Aidance Scientific, Inc.
**Company and Violations**
Aidance Scientific, Inc., based in Woonsocket, Rhode Island, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on October 1, 2026, for marketing an unapproved new drug. The product in question, "Terragen HG Formula," is sold through the company's website and Amazon storefront with claims to treat genital herpes symptoms and sores. FDA investigators identified the violation during a website review in July 2026. The agency emphasized that unapproved drugs marketed for sexually transmitted infections present a serious public health concern, as consumers may delay proper medical care, risking complications including infertility, sepsis, and death. Additionally, inadequately treated infections may be unknowingly transmitted to sexual partners.
**Regulatory Citations and Meaning**
The warning cites sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d) and 355(a)), along with section 201(g)(1) defining the product as a drug. FDA determined that "Terragen HG Formula" is not generally recognized as safe and effective (GRASE) and therefore qualifies as a "new drug" requiring FDA approval before marketing. The agency noted that homeopathic products—which this is labeled as—receive no exemption from standard drug approval requirements, despite containing ingredients in homeopathic potencies. Product labeling describing "treatment" and "relief" of genital sores established intended drug use under 21 CFR 201.128.
**Response Timeline and Compliance Monitoring**
Aidance Scientific has 15 business days from receipt to submit a written response to FDAAdvisory@fda.hhs.gov detailing corrective actions and preventative measures. Compliance officers in the OTC and homeopathic product sectors should monitor whether the company removes disease claims from marketing materials, relabels products as cosmetics or dietary supplements, or pursues formal drug approval. Failure to respond adequately may trigger seizure or injunction proceedings. The warning letter will be publicly posted on FDA.gov, making it discoverable in regulatory searches.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Aidance Scientific, Inc. MARCS-CMS 735346 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Perry Antelman Recipient Title President Aidance Scientific, Inc. 184 Burnside Ave Woonsocket , RI 02895 United States support@aidance.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 WARNING LETTER Reference Number: 735346 To Perry Antelman: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://www.aidanceproducts.com/, and provides you and opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, the “Terragen HG Formula” product on your website and available for purchase by clicking through to your Amazon storefront is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during a review of your website https://www.aidanceproducts.com/ and your Amazon storefront 1 in July 2026. Based on our review, “Terragen HG Formula” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following ar…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to Aidance Scientific, Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aidance-scientific-inc-735346-10012026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Aidance Scientific, Inc. — FDA Warning Letter, 2026-10-01: Unapproved New Drugs. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-aidance-scientific-inc-2026-10-01-unapproved-drug
"Aidance Scientific, Inc. — FDA Warning Letter, 2026-10-01: Unapproved New Drugs." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-aidance-scientific-inc-2026-10-01-unapproved-drug.
Argus HQ Research. "Aidance Scientific, Inc. — FDA Warning Letter, 2026-10-01: Unapproved New Drugs." Digital Empire Holdings LLC. Accessed October 7, 2026. https://argushq.ai/fda/warning-letter/fda-wl-aidance-scientific-inc-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_aidance_scientific_inc_2026_10_01_unapproved_drug_2026,
title = {Aidance Scientific, Inc. — FDA Warning Letter, 2026-10-01: Unapproved New Drugs},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-aidance-scientific-inc-2026-10-01-unapproved-drug},
note = {Accessed: October 7, 2026}
}